Home > Resources > Whitepapers > EPR – The ‘Workhorse Technique’ That is Still Enabling Scientists to Break New Ground After 70+ Years

EPR – The ‘Workhorse Technique’ That is Still Enabling Scientists to Break New Ground After 70+ Years

November 25, 2018

A surprisingly large number of materials have unpaired electrons. These include free radicals, many transition metal ions, and defects in materials. Free radicals are often short-lived, but play crucial roles in many significant processes such as photosynthesis, oxidation, catalysis, and polymerization reactions.

Spotlight

FiberCloud

FiberCloud is now part of Green House Data, a national data center provider offering cloud hosting, colocation, and managed IT services

OTHER WHITEPAPERS

Taking the Lead on Lab Cybersecurity

whitePaper | October 21, 2022

Just as thieves developed a new interest in explosives following the 1861 invention of the combination lock—and the concurrent rise in the popularity of bank vaults.

Harnessing the power of the human microbiome

whitePaper | January 20, 2023

We provide an overview of the human microbiome market, the observed challenges, how to overcome them and introduce future opportunities for pharmaceutical.

Internal Co-ordination Group for Biotechnology

whitePaper | October 19, 2022

The Organisation for Economic Co-operation and Development and its member countries have been addressing issues related to biotechnology since 1982.

A digital ecosystem for Clinical Trails

whitePaper | July 30, 2021

Clinical trials are complex, lengthy, and resource-inefficient. The clinical research industry is responsible for the delivery of medical solutions to society by systematically evaluating their safety and efficacy in humans during so-called clinical trials. As exemplified by the COVID-19 pandemic, a steady and efficient influx of vaccines, therapeutics, and other innovative medical solutions is critical for meeting society’s current and future medical needs. Unfortunately, the industry faces several persistent issues that make clinical trial operations overly complex, lengthy, and resource-inefficient.

Document quality control emerges as a discipline in its own right

whitePaper | November 19, 2022

Compiling a quality regulatory submission is a basic requirement for biopharmaceutical companies. Poor quality documents could lead to rejection of a regulatory application,

BIOTECHNOLOGY INNOVATION ORGANIZATION

whitePaper | January 4, 2022

The Biotechnology Innovation Organization (BIO) appreciates the opportunity to participate in the 2022 Special 301 Review: Identification of Countries under Section 182 of the Trade Act of 1974: Request for Public Comment and Announcement of Public Hearing.